|
**Overview**: Diabetes Screen Panel**Introduction**: The Diabetes Screen Panel is a diagnostic tool designed to screen for diabetes risk using serum and plasma samples. In India, diabetes affects ~77 million adults (prevalence ~11 percent), with a large undiagnosed proportion (~50 percent) in rural and low-SES populations due to limited access to testing, poor awareness, and delayed screening. Early detection of hyperglycemia prevents complications like retinopathy, nephropathy, neuropathy, and cardiovascular disease. High burden from underdiagnosis leading to advanced disease at presentation, increased healthcare costs, and reduced quality of life. Per endocrinology practices aligned with ICMR, RSSDI, and National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS) guidelines, the test employs spectrophotometry for fasting glucose and HbA1c over 1-2 days with high accuracy, valuable for opportunistic and community screening. This diagnostic falls under diabetes screening and targets individuals with risk factors (age >30, family history, obesity, sedentary lifestyle), addressing accurate detection to guide lifestyle modification, metformin initiation, or further evaluation. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating early intervention, and reducing long-term complications. Its serum/plasma-based approach ensures reliable performance in India's diverse laboratory settings.**Other Names**: Diabetes Scr Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry, compliant with 2025 standards.**Historical Milestone**: HbA1c integrated into screening; in India, key component of NPCDCS.**Purpose**: The test screens for 2 parameters including fasting glucose and HbA1c to guide diabetes risk assessment, detect hyperglycemia, inform preventive measures.**Test Parameters**: 1. Fasting Glucose, 2. HbA1c.**Pretest Condition**: Fasting 10-12 hours required; patients should report polyuria, thirst, weight loss, or risk factors.**Specimen**: 3 mL serum in 1 SST and plasma in NaF tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on symptoms, family history, obesity, hypertension, physical activity.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated hyperglycemia including complications, benefits of early detection, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using spectrophotometry by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or recent meals can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Elevated glucose/HbA1c indicates diabetes/prediabetes risk, necessitating specialist input. Normal may require follow-up in high-risk individuals.**Specialist Consultation**: Diabetologists or general physicians should be consulted for management.**Additional Supporting Tests**: OGTT, lipid profile for confirmation.**Test Limitations**: HbA1c affected by hemoglobinopathies; comprehensive approach required.**References**: Indian Journal of Endocrinology 2024, Diabetes Studies India 2023. |
